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Effects of the combination of an angiotensin II antagonist with
an HMG-CoA reductase inhibitor in experimental diabetes.
Background. Angiotensin II type 1 (AT1) receptor antago-
nists and 3-hydroxy-3-methylglutaryl conenzyme A (HMG-
CoA) reductase inhibitors have been shown to confer renopro-
tection. However, the renal effects of the combination of an
AT1 receptor antagonist and an HMG-CoA reductase inhibi-
tor in experimental diabetes are unknown.
Methods. Diabetes was induced by injection of streptozo-
tocin in Wistar rats. Diabetic rats were randomly treated with
losartan, an AT1 receptor antagonist, or simvastatin, an HMG-
CoA reductase inhibitor, as well as the combination of both
for eight weeks. Albumin excretion rate (AER) and plasma
concentrations of blood urea nitrogen (BUN), creatinine, cho-
lesterol, and triglycerides were measured. Renal injury was eval-
uated. Immunohistochemical staining of transforming growth
factor 1 (TGF1) and vascular endothelial growth factor
(VEGF) were performed.
Results. Increased AER in diabetic rats was attenuated by
treatment with either losartan or simvastatin and further re-
duced by the combination of the two. Elevated plasma concen-
trations of BUN and creatinine were only reduced by the com-
bination. There was no significant difference in plasma
concentrations of cholesterol and triglycerides between control
and diabetic rats and neither was influenced by losartan or
simvastatin. Kidney pathologic injury was attenuated by losar-
tan, but not simvastatin, compared to diabetic animals. Overex-
pression of TGF1 and VEGF was observed in the glomeruli
of diabetic rats and was attenuated by losartan, simvastatin,
or the combination of both to a similar level.
Conclusion. The combination of an angiotensin antagonist
with an HMG-CoA reductase inhibitor confers superiority over
monotherapies on renal function, as assessed by prevention of
albuminuria and rise in plasma BUN and creatinine. However,
no advantage of combination therapy was seen with respect
to attenuating renal structural injury and renal expression of
TGF and VEGF in experimental diabetes.
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Diabetic nephropathy is the leading cause of end-stage
renal disease and a major cause of morbidity and mortal-
ity in the western world. Experimental and clinical studies
over the last two decades have suggested that albumin-
uria, per se, may not only be a marker of renal injury
but also an independent risk factor for the progression
of kidney damage in diabetes. Amelioration of albumin-
uria is now considered one of the targets in the preven-
tion and retardation of diabetic nephropathy.
Clinical and experimental studies have shown that
blockade of the renin angiotensin system with an angio-
tensin II type 1 (AT1) receptor antagonist can retard the
progression of kidney injury, including reducing albumin-
uria [1]. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitor (statins) have been previously
demonstrated in diabetic patients the ability to reduce
albuminuria [2, 3]. In experimental diabetes, fluvastatin
has been shown to reduce albuminuria [4]. Furthermore,
administration of statins in experimental diabetes has
previously been reported to be associated with a reduc-
tion in the renal expression of the prosclerotic cytokine,
transforming growth factor-1 (TGF-1) [5]. A recent
meta-analysis provided evidence that statins reduce the
rate of decline in renal function in a group of subjects
with predominantly nondiabetic renal diseases [6]. There
was a trend toward reduction in proteinuria or albumin-
uria with statins, but this did not reach statistical signifi-
cance [6].
Renal protection with either an AT1 receptor antago-
nist or an HMG-CoA reductase inhibitor as monother-
apy is suboptimal. A recent study has demonstrated that
fluvastatin, an HMG-CoA reductase inhibitor, enhances
the inhibitory effects of the AT1 receptor antagonist,
valsartan, on vascular neointimal formation [7]. This sug-
gests that statins may enhance the vasoprotective actions
of AT1 receptor antagonist. In a rat model of passive
Heymann nephritis, addition of simvastatin to the angio-
tensin-converting enzyme (ACE) inhibitor, lisinopril, re-
sulted in greater reduction in proteinuria than was seen
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with lisinopril alone [8]. These data suggest that a therapy
combining an ACE inhibitor with a statin may be useful
in progressive renal disease. Furthermore, the renal ef-
fects of statins may be independent from their lipid-
lowering effects [8]. However, there are no reports as of
yet from either clinical or animal studies to determine
if combining an AT1 receptor antagonist with an HMG-
CoA reductase inhibitor leads to superior renoprotec-
tion in diabetes than with either agent alone.
Therefore, the aim of the present study was to assess
the renal effects of a combination of an AT1 receptor
antagonist with an HMG-CoA reductase inhibitor in ex-
perimental diabetes. In addition, we explored the effects
of these therapies on protein expression of TGF-1
[9, 10] and vascular endothelial growth factor (VEGF),
which were considered to be important mediators of
injury leading to kidney injury in diabetes [11, 12].
METHODS
Animals
Eight-week-old Wistar rats, both male and female
(body weight, 220–230 g), housed at the Biological Re-
search Laboratory in Shanxi Medical University, were
used in this study. The research protocol was in accordance
with the principles approved by the animal ethics commit-
tee of Shanxi Medical University. Diabetes was induced by
intraperitoneal injection of streptozotocin (Boehringer-
Mannheim, Mannheim, Germany) at a dose of 60 mg/kg
in citrate following 16-hour fasting. The animals had
access ad libitum to water and standard rat chow.
Drug therapy
Following the induction of diabetes, the animals were
randomly allocated into 4 groups with 10 rats per group
(male/female 5/5) and treated for 8 weeks. The groups
are as follows: (1) diabetic rats with no treatment; (2)
diabetic rats treated with the AT1 receptor antagonist,
losartan, at a dose of 20 mg/kg/body weight/day by gavage
(D  losartan); (3) diabetic rats treated with the HMG-
CoA reductase inhibitor, simvastatin, 2 mg/kg/day by ga-
vage (D simvastatin); and (4) diabetic rats treated with
the combination of both losartan and simvastatin at the
doses described above (D  losartan  simvastatin). In
addition, 10 age-matched nondiabetic rats were gavaged
with the vehicle daily and served as controls (N  10).
Metabolic parameters and tissue collection
Body weight was measured at the conclusion of the
experiment. Prior to sacrifice, animals were placed in
metabolic cages (Iffa Credo, L’Arbresele, France) for
collection of urine over 24 hours for measurement of
albumin concentration by radioimmunoassay (RIA) as
previously described [13]. Animals were then anesthe-
tized by intravenous injection of pentobarbitone sodium
(60 mg/kg/body weight). A midline incision of the abdo-
men was cut and blood samples were collected from
the aorta for measurement of plasma concentrations of
glucose, creatinine, blood urea nitrogen (BUN), total
cholesterol, and triglycerides by autoanalyzer (Beckman
Instruments, Palo Alto, CA, USA). Kidneys were re-
moved and fixed in 10% formalin and processed in paraf-
fin for subsequent histologic assessment and immunohis-
tochemical studies.
Kidney histopathology
Evidence of glomerulosclerosis and tubulointerstitial
injury were performed as described previously [14]. In
brief, kidney sections were stained with hematoxylin and
eosin and observed under a light microscope in a masked
fashion at a magnification of 400 using the Imaging
Analysis System (AIS; Imaging Research, St. Catherines,
Ontario, Canada) associated with a video camera and
computer. All glomeruli in each kidney section (150)
were graded according to the severity of the glomerular
damage: 0, normal; 1, slight glomerular damage of the
mesangial matrix and/or hyalinosis with focal adhesion
involving 25% of the glomerulus; 2, sclerosis of 25% to
50%; 3, sclerosis of 50% to 75%; and 4, sclerosis of75%
of the glomerulus. Tubulointerstitial area in the cortex
was evaluated and graded as: 0, normal; 1, the area of
interstitial inflammation and fibrosis, tubular atrophy
and dilation with cast formation involving 25% of the
field; 2, lesion area between 25% and 50% of the field;
and 3, lesions involving 50% of the field. The indices
for glomerulosclerosis and tubulointerstitial injury were
calculated by averaging the grades assigned to all glomer-
uli and tubule fields, respectively.
Expression of TGF-1 and VEGF
Expression of TGF-1 and VEGF was assessed by
using immunohistochemical techniques [15]. In brief, fol-
lowing dewaxing, sections were treated in a microwave
oven at low power for 10 minutes in 10 mmol/L sodium
citrate buffer (pH 6.0) [16]. Endogenous peroxidase was
inactivated using 3% hydrogen peroxide (H2O2) in meth-
anol for 20 minutes, then blocked with protein blocking
agent for 20 minutes. The kidney sections were incubated
overnight with a rabbit polyclonal antibody to TGF-1
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA)
or mouse monoclonal antibody to VEGF (Santa Cruz
Biotechnology, Inc.). Biotinylated horse anti-rabbit or
antimouse immunoglobulin (Vector Laboratories, Bur-
lingame, CA, USA) was used as a second antibody, fol-
lowed by horseradish peroxidase–conjugated streptavi-
din. Peroxidase activity was identified by reaction with
3,3-diaminobenzidine tetrahydrochloride (DAB; Sigma
Chemical Co., St. Louis, MO, USA). Quantification of
TGF-1 and VEGF immunostaining was performed by
calculation of the proportion of area occupied by the
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Table 1. Body weight, plasma glucose, cholesterol and triglycerides in rats after treatment with losartan, simvastatin or the combination
Body weight Glucose TC TG
Group N Male/female g mmol/L mmol/L mmol/L
Control 10 5/5 2615 5.20.1 1.560.02 0.510.01
Diabetic 8 4/4 2146a 23.30.9a 1.510.05 0.790.04
D  Losartan 7 4/3 2212a 25.11.0a 1.880.10 0.650.03
D  Simvastatin 6 5/1 2215a 23.90.6a 1.520.05 0.680.02
D  Losartan  Simvastatin 10 5/5 2104a 21.80.6a 1.350.03 0.580.02
Abbreviations are: TC, total cholesterol; TG, triglycerides.
aP  0.05 vs. control
brown staining in all glomeruli or tubular area per section
using the Imaging Analysis System (Imaging Research)
associated with a video camera and computer as de-
scribed previously [17].
Statistical analysis
Only animals that survived until the conclusion of the
experiment and whose plasma glucose concentrations
were greater than 15 mmol/L were included. Specifically,
44 rats survived until the end of the experiment with 6
deaths during the first week of induction of diabetes (2
deaths caused by gavage error and 4 deaths probably
caused by hyperglycemia or hypoglycemia). Among the
44 surviving rats, 3 were excluded because plasma glu-
cose levels in these rats were less than 15 mmol/L. Data
were analyzed by analysis of variance (ANOVA) using
Statview SE Graphics (Brainpower, Calabasas, CA,
USA) on a Macintosh computer (iMac, Cupertino, Cali-
fornia, USA). Comparisons of group means were per-
formed by Fisher’s least significant difference method.
Because albuminuria data did not have a normal distri-
bution, this parameter was analyzed after logarithmic
transformation. Data are shown as mean  SEM unless
otherwise specified. A P value less than 0.05 was viewed
as statistically significant.
RESULTS
Metabolic parameters
Diabetic animals had reduced weight gain and in-
creased plasma glucose concentration (Table 1). How-
ever, these parameters were not significantly influenced
by any of the drug therapies.
There was no significant difference in plasma total
cholesterol and triglycerides between control and dia-
betic rats (Table 1). These parameters were not signifi-
cantly influenced by any treatment.
Albuminuria
Albumin excretion rate was significantly increased in
diabetic rats when compared to control rats (P  0.01,
Fig. 1A). Treatment with both losartan and simvastatin
attenuated the increase in albuminuria in the diabetic
rats, but this level was still higher than that observed in
control rats. The combination of losartan and simvastatin
was associated with a further reduction in albuminuria
than was seen with either drug administrated alone, the
similar albumin excretion rate (AER) level to that ob-
served in control animals (Fig. 1A).
Plasma concentrations of BUN and creatinine
Plasma concentrations of BUN and creatinine were
moderately elevated in diabetic animals (Fig. 1 B and
C). These two parameters were not significantly influ-
enced by either losartan or simvastatin treatment. How-
ever, the combination of losartan and simvastatin was
associated with reduction in both BUN and creatinine
concentrations (Fig. 1 B and C).
Kidney histology
The diabetic rats had an increase in glomerulosclerosis
index when compared to control animals (Figs. 2 and 3A).
This increased glomerulosclerosis index in diabetic rats
was reduced by treatment with losartan. Treatment with
simvastatin was associated with a trend toward lesser
glomerulosclerosis index, but this did not reach statistical
significance. The combination of losartan with simva-
statin was associated with a reduced glomerulosclerosis
index when compared to untreated diabetic rats but was
not significantly different to that seen in rats receiving
either monotherapy.
Diabetic rats had an increase in the tubulointerstitial
injury index when compared to control rats (Fig. 3B).
All treatments were associated with a trend toward less
tubulointerstitial injury index, but this did not reach sta-
tistical significance.
TGF-1 expression
TGF-1 protein immunostaining was observed in the
glomerulus and, to a lesser degree, the tubulointerstitium
in control rats (Fig. 4). Immunostaining for TGF-1 was
increased in the diabetic kidney (12.1 0.4% vs. control,
6.8  0.4%, P  0.01). TGF-1 protein expression was
reduced by treatment with either losartan (7.3  0.5%)
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Fig. 1. Albumin excretion rate (A ), plasma BUN (B ), and creatinine
(C ) in control, untreated diabetic rats, and diabetic animals after 8
weeks treatment with losartan (D losartan), simvastatin (D simvas-
tatin), and the combination (D losartan simvastatin). Albuminuria
was expressed as geometric mean /	 tolerance factor (mg/day). *P 
0.05 vs. control; †P  0.05 vs. diabetic; ‡P  0.05 vs. D  losartan and
D  simvastatin. BUN is blood urea nitrogen.
or simvastatin (8.5  0.4%) to levels similar to those
seen in control rats. The combination of losartan and
simvastatin did not result in further reduction in renal
TGF-1 expression (7.0  0.5%).
VEGF expression
VEGF immunostaining was observed in the glomeru-
lus and in the tubulointerstitium in control rats (Fig. 5).
Immunostaining for VEGF was increased in the diabetic
Fig. 2. Representative photomicrographs of glomeruli with hematoxy-
lin and eosin in control (A ), untreated diabetic rats (B ), and diabetic
animals after 8 weeks treatment with losartan (C ), simvastatin (D ),
and the combination (E ).
kidney (21.0  2.2% vs. control, 9.8  0.7%, P  0.01).
VEGF protein expression was reduced by treatment with
either losartan (10.9 0.8%) or simvastatin (12.9 0.9%)
to levels similar to those seen in control rats (9.8 
0.7%). The combination of losartan and simvastatin did
not result in a further reduction in VEGF immunostain-
ing (10.5  0.9%).
DISCUSSION
The present study has demonstrated that the both an
angiotensin II receptor antagonist and an HMG-CoA
reductase inhibitor attenuate the increase in albuminuria
and overexpression of TGF-1 and VEGF in the kidney
of experimental diabetes. The combination of losartan
and simvastatin was associated with a further attenuation
of reduction in albuminuria. Furthermore, the combina-
tion prevented the diabetes-associated increase in plasma
concentrations of creatinine and urea, a marker of renal
function. This phenomenon was not observed with either
monotherapy. These findings provide evidence that the
combination of an angiotensin II antagonist and an
HMG-CoA reductase inhibitor may provide a new thera-
peutic approach to optimal renoprotection in diabetes.
In the present study, increased albuminuria in diabetic
rats was attenuated by both losartan and simvastatin to
a similar level, albeit this parameter was not normalized
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Fig. 3. Glomerulosclerosis (A ) and tubulointerstitial injury indices (B )
in control, untreated diabetic rats, and diabetic animals after 8 weeks
treatment with losartan (D  losartan), simvastatin (D  simvastatin),
and the combination (D losartan simvastatin). *P 0.05 vs. control;
†P  0.05 vs. diabetic.
by these monotherapies, which is still higher than that
observed in control rats. These findings are consistent
with our previous reports that described the reduction
in albuminuria by angiotensin II antagonists in diabetic
rats [14] and by HMG-CoA reductase inhibitor in a
model of hemodynamic-mediated renal injury, subtotal
nephrectomized rats [18]. The present study confirms
that the antiproteinuric effects of HMG-CoA reductase
inhibitors also occur in experimental diabetes.
The combination of losartan and simvastatin was asso-
ciated with a further reduction in albuminuria than either
agent alone. The mechanisms underlying this combina-
tion, leading to further reduction in albuminuria, are un-
known. It is possible that the statins may directly influence
the renin-angiotensin system (RAS). Recent studies have
Fig. 4. Representative photomicrographs of immunohistochemical stain-
ing of TGF-1 in control (A ), untreated diabetic rats (B ), and diabetic
animals treated with losartan (C ), simvastatin (D ), and the combination
(E ). TGF-1 is transforming growth factor 1. Reproduction of this
figure in color was made possible by Merck Research Laboratories.
Fig. 5. Representative photomicrographs of immunohistochemical
staining of VEGF in control rats (A ), untreated diabetic rats (B ), and
diabetic animals treated with losartan (C ), simvastatin (D ), and the
combination (E ). VEGF is vascular endothelial growth factor. Repro-
duction of this figure in color was made possible by Merck Research
Laboratories.
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suggested that statins may downregulate the AT1 recep-
tor expression and partly mediate the angiotensin II–
induced vascular function [19, 20].
The present study has confirmed an increase in
TGF-1 expression in the diabetic kidney and further
demonstrated that this increase was prevented not only
by treatment with the angiotensin II antagonist, losartan,
but also with the HMG-CoA reductase inhibitor, simvas-
tatin. TGF-1 has been consistently suggested to play a
key role in the pathogenesis of glomerulosclerosis and
tubulointerstitial fibrosis in progressive renal disease, in-
cluding diabetic nephropathy [21]. Blockade of the RAS
with either an ACE inhibitor or an AT1 receptor antago-
nist significantly reduces the expression of this proscle-
rotic cytokine [22]. However, the combination of losartan
and simvastatin was not associated with further reduc-
tion in TGF-1expression. This is consistent with the
view that there is not a direct correlation between block-
ade of the RAS and reduction in TGF-1. Indeed, more
potent blockade of the RAS by combined ACE inhibi-
tion and angiotensin II receptor antagonism is not associ-
ated with further reduction in TGF-1 expression when
compared to monotherapies [14, 23, 24].
The present study showed increased VEGF expression
in the diabetic rat kidney, consistent with previous find-
ings by several groups [25–27]. The increase in VEGF
was not only attenuated by the AT1 receptor antagonist
[28], but also by the HMG-CoA reductase inhibitor sim-
vastatin. This suggests that the beneficial effects of statins
include not only attenuation of TGF-1, but also of
VEGF within the kidney. Several studies have shown
that statins may have other biologic effects, including
regulating the expression of a range of cytokines and
growth factors [29]. As demonstrated in the present
study, the regulatory effects of simvastatin on TGF-1
and VEGF occurred in the setting of no significant influ-
ence on plasma cholesterol and triglycerides. These find-
ings support the view that statins may confer renal pro-
tection independent of their effects as lipid-lowering
agents [29].
In this model of experimental diabetes, in association
with increase in albuminuria, there was a modest increase
in plasma creatinine and urea concentrations in diabetic
animals. These parameters of renal function were only
prevented by the combined treatment of losartan and
simvastatin. Although not explained in the present study,
this is consistent with superior renoprotection by the
combination and complementary to the findings with
respect to albuminuria. Indeed, a previous study has
evaluated the effects of the ACE inhibitor, enalapril, and
lovastatin on renal function in diabetic rats and showed a
possible superiority of the combination over enalapril,
but not lovastatin treatment [30].
In the present study, there was no clear-cut evidence of
a superiority of combination therapy on renal structural
parameters or expression of growth factors. This lack
of superiority of combination over monotherapies may
partly relate to the number of rats studied per group, or
to the duration of diabetes only lasting eight weeks.
However, in another study of eight weeks’ duration, no
superiority of the combination of enalapril with lovas-
tatin was seen on mesangial matrix expression [30].
These data are consistent with previous studies, indicat-
ing that there is not a direct correlation between func-
tional and structural markers of diabetic nephropathy.
Indeed, in studies using a neutralizing antibody to TGF-
1, despite effects on renal extracellular matrix accumu-
lation, no effects on albuminuria were observed [9].
CONCLUSION
One must be cautious in extrapolating experimental
data to the clinical context. However, AT1 receptor an-
tagonists, although effective in retarding the progression
of human diabetic nephropathy, do not confer total reno-
protection. Therefore, it is important to identify addi-
tional strategies to not only retard but also to revise
diabetic renal disease. In the context of known cardio-
protective effects of statins, including in diabetes [31], it
is now warranted to further explore whether this class
of agents can be used to confer superior renal protection
in diabetes.
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